In summary, WEE1 does not appear to be a worthy target in the treatment of SCLC, as the efficacy of WEE1 inhibitors is quite limited and its potential has yet to be fully explored in subtype-specific therapy. The gene discussed is WEE1; the disease is small cell lung carcinoma.